NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CLDI

Calidi Biotherapeutics Inc

Jun 30 • 04:00PM ET

0.2300

Dollar change +0.0063
Percentage change 2.82	%

Healthcare • Biotechnology • USA • AMEX

Peers: BNTX MRNA GILD VRTX REGN BMY AMGN PFE JNJ LLY

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.84	Insider Own	6.57%	Shs Outstand	31.79M	Perf Week	-19.30%
Market Cap	7.31M	Forward P/E	-	EPS next Y	-0.32	Insider Trans	0.00%	Shs Float	29.70M	Perf Month	-38.96%
Enterprise Value	1.72M	PEG	-	EPS next Q	-0.11	Inst Own	17.13%	Short Float	1.23%	Perf Quarter	-64.62%
Income	-21.57M	P/S	-	EPS this Y	84.85%	Inst Trans	4.39%	Short Ratio	0.48	Perf Half Y	-84.14%
Sales	0.00M	P/B	1.05	EPS next Y	28.89%	ROA	-177.17%	Short Interest	0.37M	Perf YTD	-80.00%
Book/sh	0.22	P/C	0.69	EPS next 5Y	53.95%	ROE	-238.50%	52W High	3.89 -94.09%	Perf Year	-88.38%
Cash/sh	0.34	P/FCF	-	EPS past 3/5Y	- -	ROIC	-234.69%	52W Low	0.20 13.47%	Perf 3Y	-99.77%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	16.40% 13.71%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	81.73%	Oper. Margin	-	ATR (14)	0.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.12	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	23.29	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.12	EPS Q/Q	90.94%	SMA20	-24.90%	Beta	0.94	Target Price	10.00
Payout	-	Debt/Eq	0.68	Sales Q/Q	-	SMA50	-40.54%	Rel Volume	0.61	Prev Close	0.22
Employees	28	LT Debt/Eq	0.32	Earnings	May 14 AMC	SMA200	-76.80%	Avg Volume	768.81K	Price	0.23
IPO	Nov 01, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	-20.00% -	Trades		Volume	471,742	Change	2.82%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-22-23	Initiated	H.C. Wainwright	Buy	$11
Oct-09-23	Initiated	Robert W. Baird	Outperform	$9

Jun-27-25 08:00AM	Calidi Biotherapeutics Announces Shareholder Letter from CEO (GlobeNewswire)
Jun-02-25 08:00AM	Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting (GlobeNewswire)
May-16-25 09:55AM	Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-14-25 04:30PM	Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights (GlobeNewswire) -8.47%
Apr-28-25 08:00AM	Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Apr-25-25 08:00AM	Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 (GlobeNewswire)
Apr-23-25 08:00AM	Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director (GlobeNewswire)
Apr-22-25 08:00AM	Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 (GlobeNewswire) +6.59%
Apr-17-25 08:00AM	Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors (GlobeNewswire)
Apr-10-25 08:00AM	Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor (GlobeNewswire)
Mar-31-25 04:30PM	Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -12.89%
04:10PM	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights (GlobeNewswire)
Mar-28-25 09:00AM	Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -6.53%
Mar-26-25 08:00AM	Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma (GlobeNewswire)
Mar-14-25 09:00AM	Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire) +9.25%
02:00PM	Loading…
Mar-11-25 02:00PM	IBN Coverage: Calidi Biotherapeutics (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform (NewMediaWire)
Mar-10-25 08:00AM	Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform (GlobeNewswire) -7.07%
Feb-28-25 09:00AM	Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire) +5.56%
Feb-24-25 08:00AM	Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital (GlobeNewswire) -7.52%
Jan-29-25 08:00AM	Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5 (GlobeNewswire)
Jan-28-25 08:00AM	Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement (GlobeNewswire)
Jan-13-25 08:00AM	Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025 (GlobeNewswire)
Jan-10-25 04:30PM	Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock (GlobeNewswire) -32.22%
08:30AM	Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock (GlobeNewswire)
Jan-08-25 04:01PM	Calidi Biotherapeutics Announces Proposed Public Offering (GlobeNewswire) -8.16%
Nov-18-24 08:00AM	Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer (GlobeNewswire) +7.31%
Nov-15-24 04:05PM	Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock (GlobeNewswire) +8.96%
Nov-14-24 08:30AM	Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock (GlobeNewswire) -40.53%
Nov-13-24 04:33PM	Calidi Biotherapeutics Announces Proposed Public Offering (GlobeNewswire) +60.19%
Nov-12-24 05:29PM	Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) +26.35%
09:00AM	Loading…
Oct-25-24 09:00AM	Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +29.76%
Oct-24-24 08:35AM	Calidi to sell 2.05M shares at $1.00 in registered direct offering (TipRanks)
08:30AM	Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences (GlobeNewswire)
Oct-23-24 08:31AM	Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -26.54%
Oct-19-24 05:48PM	Calidi Biotherapeutics Faces Warrant Delisting by NYSE (TipRanks)
Oct-18-24 11:00PM	NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS) (GlobeNewswire) -7.38%
08:45AM	Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Sep-30-24 08:00AM	Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma (GlobeNewswire) -5.79%
Aug-13-24 05:37PM	Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -5.71%
Aug-02-24 09:00AM	GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) -8.38%
Jul-29-24 09:00AM	Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor (GlobeNewswire)
Jul-18-24 08:00AM	Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform (GlobeNewswire) -8.43%
Jul-16-24 08:00AM	Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board (GlobeNewswire) +7.42%
Jul-05-24 04:15PM	Calidi to Effect Reverse Stock Split (Business Wire) -18.30%
Jun-27-24 07:00AM	Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors (Business Wire)
Jun-11-24 04:05PM	Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13 (Business Wire) +31.71% -16.67%
Jun-10-24 07:00AM	Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidis Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors (Business Wire) +6.22%
Jun-03-24 07:00AM	Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting (Business Wire) +15.79%
May-31-24 08:51AM	Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds (Business Wire) -36.67%
May-24-24 09:00AM	ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
May-17-24 09:00AM	Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV (ACCESSWIRE) -5.99%
May-14-24 04:05PM	Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results (Business Wire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +7.95%
May-01-24 07:00AM	Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting (Business Wire)
Apr-23-24 07:00AM	Join Calidi Biotherapeutics Exclusive Live Investor Webinar and Q&A Session on April 24 (Business Wire) +7.05%
Apr-19-24 04:05PM	Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering (Business Wire)
Apr-16-24 08:31AM	Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering (Business Wire) -65.48%
Apr-09-24 07:00AM	Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Companys Novel Immunotherapies at the AACR Annual Meeting 2024 (Business Wire) +62.39%
Mar-15-24 04:05PM	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results (Business Wire) -5.81%
Mar-11-24 07:00AM	Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer (Business Wire)
Feb-12-24 07:00AM	Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference (Business Wire)
Jan-08-24 07:00AM	Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board (Business Wire) +6.84%
Dec-13-23 07:00AM	Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit (Business Wire)
Dec-12-23 07:00AM	Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors (Business Wire)
Nov-20-23 07:00AM	Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones (Business Wire)
Nov-14-23 04:05PM	Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results (Business Wire) -6.98%
Nov-03-23 07:00AM	Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancers 38th Annual Meeting (SITC 2023) (Business Wire) +18.90%
Nov-01-23 07:00AM	Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment (Business Wire) -10.55%
Oct-30-23 07:00AM	Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer (Business Wire) -13.19%
Oct-10-23 07:00AM	Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023 (Business Wire)
Sep-13-23 05:50AM	Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies (GlobeNewswire) -38.75%
Sep-11-23 04:05PM	First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments (GlobeNewswire) -5.66%
Aug-24-23 12:06PM	FIRST LIGHT ACQUISITION GROUP, INC. Further Adjourns Special Meeting of Stockholders to August 28, 2023 at 10:30 am ET (GlobeNewswire)
Aug-22-23 11:41AM	FIRST LIGHT ACQUISITION GROUP, INC. Adjourns Special Meeting of Stockholders to August 24, 2023 at 10:30 am ET (GlobeNewswire) -10.85%
Aug-16-23 06:00AM	Flag Stockholders: Reminder to Vote for Proposed Business Combination (GlobeNewswire)
Aug-07-23 05:00AM	First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination (GlobeNewswire)
Jun-23-23 05:00AM	Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer (GlobeNewswire)

Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Camaisa Allan	CEO and Chairman of the Board	Dec 17 '24	Sale	1.62	10,000	16,200	66,712	Dec 18 09:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLDI

Calidi Biotherapeutics Inc

Upgrade your FINVIZ experience